Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 4;40(21):3707–3718. doi: 10.1038/s41388-021-01808-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A, B Western blot showing protein expression in naïve A375 cells and two resistant lines with increasing levels of vemurafenib resistance probed for (A) LRIG1 and (B) EGFR. The blots have been cropped vertically for clarity. Quantifications are indicated as the LRIG1/Actin or EGFR/Actin fold change from A375 respectively. C Proliferation (normalized WST intensity) after treatment with recombinant protein in four different cell lines. Normalization and statistics were performed as in Fig. 6B. Concentrations of supplemented proteins are indicated for recombinant LRIG1 ectodomain (sLRIG1, blue bars) and His-MBP-Strep control protein (gray bars). D Western blots on cell lysates form vemurafenib-resistant cells, stimulated as indicated and probed for phospho-AKT and phospho-Erk1/2. Quantifications are indicated as the phospho-AKT/Actin fold change from FBS-stimulated cells treated with control peptide or as the phospho-Erk1/2/Actin fold change from serum-starved cells treated with control peptide.